Autopsy report · NCT03943147

An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

“Insufficient enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 2 years 2 months before it stopped.
• 16 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Bristol-Myers Squibb

Sponsor type

Industry

Conditions

Lupus Nephritis

Interventions

BMS-986165; Placebo; Mycophenolate Mofetil

Participants

16

Sites

100

Countries

Australia, Belgium, Canada, China, Czechia, Germany, Israel, Italy, Mexico, Netherlands, Russia, South Korea and more

Trials that died the same way

• Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma
  “Insufficient enrollment rate” (91% match in meaning)
• Treatment Prior to Injection and Biopsy of the Vulva
  “Not enough enrollment” (91% match in meaning)
• Family Nurture Intervention in the CHoNJ NICU
  “insufficient enrollment numbers” (91% match in meaning)
• Development of Auditory Skills in Young Deaf Children With Bilateral Cochlear Implants
  “Not sufficient enrollment” (89% match in meaning)
• Study to Determine the Effect of Azasite on Corneal Surface Irregularity
  “Lack of enrollment” (89% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.